nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—Anaemia—Carmustine—lymphatic system cancer	0.00076	0.00076	CcSEcCtD
Paroxetine—Back pain—Vincristine—lymphatic system cancer	0.00076	0.00076	CcSEcCtD
Paroxetine—Vomiting—Teniposide—lymphatic system cancer	0.000759	0.000759	CcSEcCtD
Paroxetine—Sepsis—Methotrexate—lymphatic system cancer	0.000756	0.000756	CcSEcCtD
Paroxetine—Agitation—Carmustine—lymphatic system cancer	0.000756	0.000756	CcSEcCtD
Paroxetine—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000753	0.000753	CcSEcCtD
Paroxetine—Asthenia—Fludarabine—lymphatic system cancer	0.000753	0.000753	CcSEcCtD
Paroxetine—Rash—Teniposide—lymphatic system cancer	0.000753	0.000753	CcSEcCtD
Paroxetine—Dermatitis—Teniposide—lymphatic system cancer	0.000752	0.000752	CcSEcCtD
Paroxetine—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000749	0.000749	CcSEcCtD
Paroxetine—Headache—Teniposide—lymphatic system cancer	0.000748	0.000748	CcSEcCtD
Paroxetine—Pruritus—Fludarabine—lymphatic system cancer	0.000742	0.000742	CcSEcCtD
Paroxetine—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.000742	0.000742	CcSEcCtD
Paroxetine—Back pain—Mitoxantrone—lymphatic system cancer	0.00074	0.00074	CcSEcCtD
Paroxetine—Leukopenia—Carmustine—lymphatic system cancer	0.000736	0.000736	CcSEcCtD
Paroxetine—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.000731	0.000731	CcSEcCtD
Paroxetine—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000727	0.000727	CcSEcCtD
Paroxetine—Anaemia—Vincristine—lymphatic system cancer	0.000726	0.000726	CcSEcCtD
Paroxetine—Agitation—Vincristine—lymphatic system cancer	0.000722	0.000722	CcSEcCtD
Paroxetine—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000721	0.000721	CcSEcCtD
Paroxetine—Polyuria—Methotrexate—lymphatic system cancer	0.000721	0.000721	CcSEcCtD
Paroxetine—Photosensitivity—Methotrexate—lymphatic system cancer	0.000721	0.000721	CcSEcCtD
Paroxetine—Hypotension—Bleomycin—lymphatic system cancer	0.000719	0.000719	CcSEcCtD
Paroxetine—Diarrhoea—Fludarabine—lymphatic system cancer	0.000718	0.000718	CcSEcCtD
Paroxetine—Convulsion—Carmustine—lymphatic system cancer	0.000713	0.000713	CcSEcCtD
Paroxetine—Hypertension—Carmustine—lymphatic system cancer	0.00071	0.00071	CcSEcCtD
Paroxetine—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00071	0.00071	CcSEcCtD
Paroxetine—Nausea—Teniposide—lymphatic system cancer	0.000709	0.000709	CcSEcCtD
Paroxetine—Anaemia—Mitoxantrone—lymphatic system cancer	0.000707	0.000707	CcSEcCtD
Paroxetine—Vertigo—Vincristine—lymphatic system cancer	0.000706	0.000706	CcSEcCtD
Paroxetine—Hepatic failure—Methotrexate—lymphatic system cancer	0.000704	0.000704	CcSEcCtD
Paroxetine—Leukopenia—Vincristine—lymphatic system cancer	0.000703	0.000703	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000701	0.000701	CcSEcCtD
Paroxetine—Chest pain—Carmustine—lymphatic system cancer	0.0007	0.0007	CcSEcCtD
Paroxetine—Myalgia—Carmustine—lymphatic system cancer	0.0007	0.0007	CcSEcCtD
Paroxetine—Anxiety—Carmustine—lymphatic system cancer	0.000698	0.000698	CcSEcCtD
Paroxetine—Paraesthesia—Bleomycin—lymphatic system cancer	0.000691	0.000691	CcSEcCtD
Paroxetine—Malaise—Mitoxantrone—lymphatic system cancer	0.00069	0.00069	CcSEcCtD
Paroxetine—Dyspnoea—Bleomycin—lymphatic system cancer	0.000686	0.000686	CcSEcCtD
Paroxetine—Renal failure acute—Methotrexate—lymphatic system cancer	0.000685	0.000685	CcSEcCtD
Paroxetine—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000685	0.000685	CcSEcCtD
Paroxetine—Convulsion—Vincristine—lymphatic system cancer	0.00068	0.00068	CcSEcCtD
Paroxetine—Hypertension—Vincristine—lymphatic system cancer	0.000678	0.000678	CcSEcCtD
Paroxetine—Confusional state—Carmustine—lymphatic system cancer	0.000677	0.000677	CcSEcCtD
Paroxetine—Oedema—Carmustine—lymphatic system cancer	0.000671	0.000671	CcSEcCtD
Paroxetine—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.000671	0.000671	CcSEcCtD
Paroxetine—Decreased appetite—Bleomycin—lymphatic system cancer	0.000669	0.000669	CcSEcCtD
Paroxetine—Myalgia—Vincristine—lymphatic system cancer	0.000669	0.000669	CcSEcCtD
Paroxetine—Visual disturbance—Methotrexate—lymphatic system cancer	0.000668	0.000668	CcSEcCtD
Paroxetine—Cough—Mitoxantrone—lymphatic system cancer	0.000667	0.000667	CcSEcCtD
Paroxetine—Infection—Carmustine—lymphatic system cancer	0.000667	0.000667	CcSEcCtD
Paroxetine—Vomiting—Fludarabine—lymphatic system cancer	0.000667	0.000667	CcSEcCtD
Paroxetine—Convulsion—Mitoxantrone—lymphatic system cancer	0.000663	0.000663	CcSEcCtD
Paroxetine—Rash—Fludarabine—lymphatic system cancer	0.000661	0.000661	CcSEcCtD
Paroxetine—Dermatitis—Fludarabine—lymphatic system cancer	0.000661	0.000661	CcSEcCtD
Paroxetine—Hypertension—Mitoxantrone—lymphatic system cancer	0.00066	0.00066	CcSEcCtD
Paroxetine—Pain—Bleomycin—lymphatic system cancer	0.000658	0.000658	CcSEcCtD
Paroxetine—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000657	0.000657	CcSEcCtD
Paroxetine—Headache—Fludarabine—lymphatic system cancer	0.000657	0.000657	CcSEcCtD
Paroxetine—Tachycardia—Carmustine—lymphatic system cancer	0.000655	0.000655	CcSEcCtD
Paroxetine—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.000654	0.000654	CcSEcCtD
Paroxetine—Chest pain—Mitoxantrone—lymphatic system cancer	0.000651	0.000651	CcSEcCtD
Paroxetine—Myalgia—Mitoxantrone—lymphatic system cancer	0.000651	0.000651	CcSEcCtD
Paroxetine—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000651	0.000651	CcSEcCtD
Paroxetine—Anxiety—Mitoxantrone—lymphatic system cancer	0.000649	0.000649	CcSEcCtD
Paroxetine—Lethargy—Methotrexate—lymphatic system cancer	0.000646	0.000646	CcSEcCtD
Paroxetine—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.000646	0.000646	CcSEcCtD
Paroxetine—Discomfort—Mitoxantrone—lymphatic system cancer	0.000643	0.000643	CcSEcCtD
Paroxetine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000641	0.000641	CcSEcCtD
Paroxetine—Oedema—Vincristine—lymphatic system cancer	0.000641	0.000641	CcSEcCtD
Paroxetine—Infection—Vincristine—lymphatic system cancer	0.000637	0.000637	CcSEcCtD
Paroxetine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000634	0.000634	CcSEcCtD
Paroxetine—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000633	0.000633	CcSEcCtD
Paroxetine—Confusional state—Mitoxantrone—lymphatic system cancer	0.000629	0.000629	CcSEcCtD
Paroxetine—Nervous system disorder—Vincristine—lymphatic system cancer	0.000629	0.000629	CcSEcCtD
Paroxetine—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000628	0.000628	CcSEcCtD
Paroxetine—Hypotension—Carmustine—lymphatic system cancer	0.000627	0.000627	CcSEcCtD
Paroxetine—Oedema—Mitoxantrone—lymphatic system cancer	0.000624	0.000624	CcSEcCtD
Paroxetine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000624	0.000624	CcSEcCtD
Paroxetine—Nausea—Fludarabine—lymphatic system cancer	0.000623	0.000623	CcSEcCtD
Paroxetine—Infection—Mitoxantrone—lymphatic system cancer	0.00062	0.00062	CcSEcCtD
Paroxetine—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00062	0.00062	CcSEcCtD
Paroxetine—Shock—Mitoxantrone—lymphatic system cancer	0.000614	0.000614	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000612	0.000612	CcSEcCtD
Paroxetine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000611	0.000611	CcSEcCtD
Paroxetine—Urticaria—Bleomycin—lymphatic system cancer	0.000611	0.000611	CcSEcCtD
Paroxetine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000609	0.000609	CcSEcCtD
Paroxetine—Body temperature increased—Bleomycin—lymphatic system cancer	0.000608	0.000608	CcSEcCtD
Paroxetine—Insomnia—Carmustine—lymphatic system cancer	0.000607	0.000607	CcSEcCtD
Paroxetine—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000606	0.000606	CcSEcCtD
Paroxetine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000603	0.000603	CcSEcCtD
Paroxetine—Paraesthesia—Carmustine—lymphatic system cancer	0.000603	0.000603	CcSEcCtD
Paroxetine—Mood swings—Methotrexate—lymphatic system cancer	0.000599	0.000599	CcSEcCtD
Paroxetine—Hypotension—Vincristine—lymphatic system cancer	0.000599	0.000599	CcSEcCtD
Paroxetine—Dyspnoea—Carmustine—lymphatic system cancer	0.000599	0.000599	CcSEcCtD
Paroxetine—Somnolence—Carmustine—lymphatic system cancer	0.000597	0.000597	CcSEcCtD
Paroxetine—Ataxia—Methotrexate—lymphatic system cancer	0.000595	0.000595	CcSEcCtD
Paroxetine—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000584	0.000584	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000584	0.000584	CcSEcCtD
Paroxetine—Decreased appetite—Carmustine—lymphatic system cancer	0.000584	0.000584	CcSEcCtD
Paroxetine—Hypotension—Mitoxantrone—lymphatic system cancer	0.000583	0.000583	CcSEcCtD
Paroxetine—Insomnia—Vincristine—lymphatic system cancer	0.00058	0.00058	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00058	0.00058	CcSEcCtD
Paroxetine—Paraesthesia—Vincristine—lymphatic system cancer	0.000575	0.000575	CcSEcCtD
Paroxetine—Constipation—Carmustine—lymphatic system cancer	0.000574	0.000574	CcSEcCtD
Paroxetine—Pain—Carmustine—lymphatic system cancer	0.000574	0.000574	CcSEcCtD
Paroxetine—Breast disorder—Methotrexate—lymphatic system cancer	0.000572	0.000572	CcSEcCtD
Paroxetine—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00057	0.00057	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000569	0.000569	CcSEcCtD
Paroxetine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000567	0.000567	CcSEcCtD
Paroxetine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00056	0.00056	CcSEcCtD
Paroxetine—Decreased appetite—Vincristine—lymphatic system cancer	0.000557	0.000557	CcSEcCtD
Paroxetine—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000556	0.000556	CcSEcCtD
Paroxetine—Somnolence—Mitoxantrone—lymphatic system cancer	0.000555	0.000555	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000553	0.000553	CcSEcCtD
Paroxetine—Feeling abnormal—Carmustine—lymphatic system cancer	0.000553	0.000553	CcSEcCtD
Paroxetine—Fatigue—Vincristine—lymphatic system cancer	0.000553	0.000553	CcSEcCtD
Paroxetine—Asthenia—Bleomycin—lymphatic system cancer	0.000552	0.000552	CcSEcCtD
Paroxetine—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000549	0.000549	CcSEcCtD
Paroxetine—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000549	0.000549	CcSEcCtD
Paroxetine—Constipation—Vincristine—lymphatic system cancer	0.000548	0.000548	CcSEcCtD
Paroxetine—Pain—Vincristine—lymphatic system cancer	0.000548	0.000548	CcSEcCtD
Paroxetine—Asthma—Methotrexate—lymphatic system cancer	0.000547	0.000547	CcSEcCtD
Paroxetine—Pruritus—Bleomycin—lymphatic system cancer	0.000544	0.000544	CcSEcCtD
Paroxetine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000543	0.000543	CcSEcCtD
Paroxetine—Eosinophilia—Methotrexate—lymphatic system cancer	0.000541	0.000541	CcSEcCtD
Paroxetine—Fatigue—Mitoxantrone—lymphatic system cancer	0.000538	0.000538	CcSEcCtD
Paroxetine—Pancreatitis—Methotrexate—lymphatic system cancer	0.000536	0.000536	CcSEcCtD
Paroxetine—Pain—Mitoxantrone—lymphatic system cancer	0.000534	0.000534	CcSEcCtD
Paroxetine—Constipation—Mitoxantrone—lymphatic system cancer	0.000534	0.000534	CcSEcCtD
Paroxetine—Abdominal pain—Carmustine—lymphatic system cancer	0.000531	0.000531	CcSEcCtD
Paroxetine—Body temperature increased—Carmustine—lymphatic system cancer	0.000531	0.000531	CcSEcCtD
Paroxetine—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000524	0.000524	CcSEcCtD
Paroxetine—Pancytopenia—Methotrexate—lymphatic system cancer	0.000519	0.000519	CcSEcCtD
Paroxetine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000514	0.000514	CcSEcCtD
Paroxetine—Dysuria—Methotrexate—lymphatic system cancer	0.000511	0.000511	CcSEcCtD
Paroxetine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00051	0.00051	CcSEcCtD
Paroxetine—Body temperature increased—Vincristine—lymphatic system cancer	0.000507	0.000507	CcSEcCtD
Paroxetine—Abdominal pain—Vincristine—lymphatic system cancer	0.000507	0.000507	CcSEcCtD
Paroxetine—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000504	0.000504	CcSEcCtD
Paroxetine—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000499	0.000499	CcSEcCtD
Paroxetine—Urticaria—Mitoxantrone—lymphatic system cancer	0.000496	0.000496	CcSEcCtD
Paroxetine—Hypersensitivity—Carmustine—lymphatic system cancer	0.000495	0.000495	CcSEcCtD
Paroxetine—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000493	0.000493	CcSEcCtD
Paroxetine—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000493	0.000493	CcSEcCtD
Paroxetine—Pneumonia—Methotrexate—lymphatic system cancer	0.00049	0.00049	CcSEcCtD
Paroxetine—Vomiting—Bleomycin—lymphatic system cancer	0.000489	0.000489	CcSEcCtD
Paroxetine—Drowsiness—Methotrexate—lymphatic system cancer	0.000488	0.000488	CcSEcCtD
Paroxetine—Depression—Methotrexate—lymphatic system cancer	0.000486	0.000486	CcSEcCtD
Paroxetine—Rash—Bleomycin—lymphatic system cancer	0.000485	0.000485	CcSEcCtD
Paroxetine—Dermatitis—Bleomycin—lymphatic system cancer	0.000485	0.000485	CcSEcCtD
Paroxetine—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000483	0.000483	CcSEcCtD
Paroxetine—Asthenia—Carmustine—lymphatic system cancer	0.000482	0.000482	CcSEcCtD
Paroxetine—Stomatitis—Methotrexate—lymphatic system cancer	0.000475	0.000475	CcSEcCtD
Paroxetine—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000474	0.000474	CcSEcCtD
Paroxetine—Hypersensitivity—Vincristine—lymphatic system cancer	0.000472	0.000472	CcSEcCtD
Paroxetine—Sweating—Methotrexate—lymphatic system cancer	0.000467	0.000467	CcSEcCtD
Paroxetine—Haematuria—Methotrexate—lymphatic system cancer	0.000465	0.000465	CcSEcCtD
Paroxetine—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000461	0.000461	CcSEcCtD
Paroxetine—Epistaxis—Methotrexate—lymphatic system cancer	0.00046	0.00046	CcSEcCtD
Paroxetine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00046	0.00046	CcSEcCtD
Paroxetine—Asthenia—Vincristine—lymphatic system cancer	0.00046	0.00046	CcSEcCtD
Paroxetine—Diarrhoea—Carmustine—lymphatic system cancer	0.000459	0.000459	CcSEcCtD
Paroxetine—Nausea—Bleomycin—lymphatic system cancer	0.000457	0.000457	CcSEcCtD
Paroxetine—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000455	0.000455	CcSEcCtD
Paroxetine—Asthenia—Mitoxantrone—lymphatic system cancer	0.000448	0.000448	CcSEcCtD
Paroxetine—Dizziness—Carmustine—lymphatic system cancer	0.000444	0.000444	CcSEcCtD
Paroxetine—Haemoglobin—Methotrexate—lymphatic system cancer	0.00044	0.00044	CcSEcCtD
Paroxetine—Diarrhoea—Vincristine—lymphatic system cancer	0.000439	0.000439	CcSEcCtD
Paroxetine—Haemorrhage—Methotrexate—lymphatic system cancer	0.000438	0.000438	CcSEcCtD
Paroxetine—Hepatitis—Methotrexate—lymphatic system cancer	0.000438	0.000438	CcSEcCtD
Paroxetine—Pharyngitis—Methotrexate—lymphatic system cancer	0.000434	0.000434	CcSEcCtD
Paroxetine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000427	0.000427	CcSEcCtD
Paroxetine—Vomiting—Carmustine—lymphatic system cancer	0.000427	0.000427	CcSEcCtD
Paroxetine—Dizziness—Vincristine—lymphatic system cancer	0.000424	0.000424	CcSEcCtD
Paroxetine—Rash—Carmustine—lymphatic system cancer	0.000423	0.000423	CcSEcCtD
Paroxetine—Dermatitis—Carmustine—lymphatic system cancer	0.000423	0.000423	CcSEcCtD
Paroxetine—Visual impairment—Methotrexate—lymphatic system cancer	0.000422	0.000422	CcSEcCtD
Paroxetine—Headache—Carmustine—lymphatic system cancer	0.000421	0.000421	CcSEcCtD
Paroxetine—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000414	0.000414	CcSEcCtD
Paroxetine—Eye disorder—Methotrexate—lymphatic system cancer	0.000409	0.000409	CcSEcCtD
Paroxetine—Tinnitus—Methotrexate—lymphatic system cancer	0.000408	0.000408	CcSEcCtD
Paroxetine—Vomiting—Vincristine—lymphatic system cancer	0.000407	0.000407	CcSEcCtD
Paroxetine—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000406	0.000406	CcSEcCtD
Paroxetine—Rash—Vincristine—lymphatic system cancer	0.000404	0.000404	CcSEcCtD
Paroxetine—Dermatitis—Vincristine—lymphatic system cancer	0.000404	0.000404	CcSEcCtD
Paroxetine—Headache—Vincristine—lymphatic system cancer	0.000401	0.000401	CcSEcCtD
Paroxetine—Nausea—Carmustine—lymphatic system cancer	0.000399	0.000399	CcSEcCtD
Paroxetine—Angiopathy—Methotrexate—lymphatic system cancer	0.000397	0.000397	CcSEcCtD
Paroxetine—Vomiting—Mitoxantrone—lymphatic system cancer	0.000397	0.000397	CcSEcCtD
Paroxetine—Immune system disorder—Methotrexate—lymphatic system cancer	0.000395	0.000395	CcSEcCtD
Paroxetine—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000394	0.000394	CcSEcCtD
Paroxetine—Rash—Mitoxantrone—lymphatic system cancer	0.000394	0.000394	CcSEcCtD
Paroxetine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000393	0.000393	CcSEcCtD
Paroxetine—Chills—Methotrexate—lymphatic system cancer	0.000393	0.000393	CcSEcCtD
Paroxetine—Headache—Mitoxantrone—lymphatic system cancer	0.000391	0.000391	CcSEcCtD
Paroxetine—Alopecia—Methotrexate—lymphatic system cancer	0.000387	0.000387	CcSEcCtD
Paroxetine—Mental disorder—Methotrexate—lymphatic system cancer	0.000383	0.000383	CcSEcCtD
Paroxetine—Malnutrition—Methotrexate—lymphatic system cancer	0.000381	0.000381	CcSEcCtD
Paroxetine—Erythema—Methotrexate—lymphatic system cancer	0.000381	0.000381	CcSEcCtD
Paroxetine—Nausea—Vincristine—lymphatic system cancer	0.000381	0.000381	CcSEcCtD
Paroxetine—Dysgeusia—Methotrexate—lymphatic system cancer	0.000373	0.000373	CcSEcCtD
Paroxetine—Nausea—Mitoxantrone—lymphatic system cancer	0.000371	0.000371	CcSEcCtD
Paroxetine—Back pain—Methotrexate—lymphatic system cancer	0.000369	0.000369	CcSEcCtD
Paroxetine—Vision blurred—Methotrexate—lymphatic system cancer	0.000359	0.000359	CcSEcCtD
Paroxetine—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000354	0.000354	CcSEcCtD
Paroxetine—Anaemia—Methotrexate—lymphatic system cancer	0.000352	0.000352	CcSEcCtD
Paroxetine—Malaise—Methotrexate—lymphatic system cancer	0.000344	0.000344	CcSEcCtD
Paroxetine—Vertigo—Methotrexate—lymphatic system cancer	0.000342	0.000342	CcSEcCtD
Paroxetine—Leukopenia—Methotrexate—lymphatic system cancer	0.000341	0.000341	CcSEcCtD
Paroxetine—Cough—Methotrexate—lymphatic system cancer	0.000332	0.000332	CcSEcCtD
Paroxetine—Convulsion—Methotrexate—lymphatic system cancer	0.00033	0.00033	CcSEcCtD
Paroxetine—Chest pain—Methotrexate—lymphatic system cancer	0.000324	0.000324	CcSEcCtD
Paroxetine—Arthralgia—Methotrexate—lymphatic system cancer	0.000324	0.000324	CcSEcCtD
Paroxetine—Myalgia—Methotrexate—lymphatic system cancer	0.000324	0.000324	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000322	0.000322	CcSEcCtD
Paroxetine—Discomfort—Methotrexate—lymphatic system cancer	0.000321	0.000321	CcSEcCtD
Paroxetine—Confusional state—Methotrexate—lymphatic system cancer	0.000314	0.000314	CcSEcCtD
Paroxetine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000311	0.000311	CcSEcCtD
Paroxetine—Infection—Methotrexate—lymphatic system cancer	0.000309	0.000309	CcSEcCtD
Paroxetine—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000305	0.000305	CcSEcCtD
Paroxetine—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000304	0.000304	CcSEcCtD
Paroxetine—Skin disorder—Methotrexate—lymphatic system cancer	0.000302	0.000302	CcSEcCtD
Paroxetine—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000301	0.000301	CcSEcCtD
Paroxetine—Hypotension—Methotrexate—lymphatic system cancer	0.000291	0.000291	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000283	0.000283	CcSEcCtD
Paroxetine—Insomnia—Methotrexate—lymphatic system cancer	0.000281	0.000281	CcSEcCtD
Paroxetine—Paraesthesia—Methotrexate—lymphatic system cancer	0.000279	0.000279	CcSEcCtD
Paroxetine—Dyspnoea—Methotrexate—lymphatic system cancer	0.000277	0.000277	CcSEcCtD
Paroxetine—Somnolence—Methotrexate—lymphatic system cancer	0.000276	0.000276	CcSEcCtD
Paroxetine—Dyspepsia—Methotrexate—lymphatic system cancer	0.000274	0.000274	CcSEcCtD
Paroxetine—Decreased appetite—Methotrexate—lymphatic system cancer	0.00027	0.00027	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000268	0.000268	CcSEcCtD
Paroxetine—Fatigue—Methotrexate—lymphatic system cancer	0.000268	0.000268	CcSEcCtD
Paroxetine—Pain—Methotrexate—lymphatic system cancer	0.000266	0.000266	CcSEcCtD
Paroxetine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000256	0.000256	CcSEcCtD
Paroxetine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000254	0.000254	CcSEcCtD
Paroxetine—Urticaria—Methotrexate—lymphatic system cancer	0.000247	0.000247	CcSEcCtD
Paroxetine—Abdominal pain—Methotrexate—lymphatic system cancer	0.000246	0.000246	CcSEcCtD
Paroxetine—Body temperature increased—Methotrexate—lymphatic system cancer	0.000246	0.000246	CcSEcCtD
Paroxetine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000229	0.000229	CcSEcCtD
Paroxetine—Asthenia—Methotrexate—lymphatic system cancer	0.000223	0.000223	CcSEcCtD
Paroxetine—Pruritus—Methotrexate—lymphatic system cancer	0.00022	0.00022	CcSEcCtD
Paroxetine—Diarrhoea—Methotrexate—lymphatic system cancer	0.000213	0.000213	CcSEcCtD
Paroxetine—Dizziness—Methotrexate—lymphatic system cancer	0.000206	0.000206	CcSEcCtD
Paroxetine—Vomiting—Methotrexate—lymphatic system cancer	0.000198	0.000198	CcSEcCtD
Paroxetine—Rash—Methotrexate—lymphatic system cancer	0.000196	0.000196	CcSEcCtD
Paroxetine—Dermatitis—Methotrexate—lymphatic system cancer	0.000196	0.000196	CcSEcCtD
Paroxetine—Headache—Methotrexate—lymphatic system cancer	0.000195	0.000195	CcSEcCtD
Paroxetine—Nausea—Methotrexate—lymphatic system cancer	0.000185	0.000185	CcSEcCtD
